Eli Lilly and Company

Jerome H Fleisch

Jason Scott Sawyer

William T Jackson

George J Cullinan

Winston S Marshall

This invention provides methods for the treatment or inhibiting of iritis which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B.sub.4 antagonist.

Leukotriene antagonists useful for treating iritis

This invention provides methods for the treatment or inhibiting of dermatitis which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B.sub.4 antagonist.

Leukotriene antagonists useful for treating dermatoses

This invention provides methods for the treatment or inhibitor of oral squamous cell carcinoma which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B.sub.4 antagonist.

Leukotriene antagonists for use in the treatment or inhibition of oral

This invention provides methods for the treatment or prevention of cerebral focal ischemia which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B.sub.4 antagonist.

Leukotriene antagonists for use in the treatment or inhibition of

This invention relates to a class of quinoline quinones, which are useful for the therapy of immediate hypersensitivity reactions, such as asthma, and in treating any condition characterized by excessive release of leukotrienes. This invention also includes a method for treating these conditions, which comprises administering to animals, including humans, an effective dose of the quinoline quinone compounds. A further part of this invention is pharmaceutical formulations containing these pharmacologically-active compounds.

Quinoline quinones and anti-asthmatic use thereof

This invention provides for novel quinoxalinedione derivatives, the use of quinoxalinedione derivatives in treating animals suffering from immediate hypersensitivity reactions and conditions characterized by excessive release of leukotrienes, and formulations of the quinoxalinedione derivatives.

Quinoxalinedione leukotriene release inhibitors

This invention relates to a class of isoquinoline quinones, which are useful for the therapy of immediate hypersensitivity reactions, such as asthma, and in treating any condition characterized by excessive release of leukotrienes. This invention also includes a method for treating these conditions, which comprises administering to animals, including humans, an effective dose of the isoquinoline quinone compounds. A further part of this invention is pharmaceutical formulations containing these pharmacologically-active compounds.

Growing community of inventors

Carmel, IN, United States of America

Jerome H Fleisch